David Quan


David Quan is a pharmacist who cares for patients in the UCSF Liver Transplant Program and UCSF Kidney Transplant Program.

Quan is the pharmacy specialist for UCSF in transplantation of solid organs – a term that comprises non-hollow internal organs such as the heart, liver and kidney. He oversees UCSF's transplant pharmacist group and serves as program director for the UCSF Medical Center's specialized residency in solid organ transplant.

Quan earned his doctor of pharmacy degree at UCSF, where he then completed a residency in clinical pharmacy. He has authored articles on suppressing the immune system in transplant recipients, various aspects of liver disease and aspects of treating disease with medications. At national meetings of health care professionals, he has been a speaker and presented research on transplant drug therapy and hepatitis C treatment.


Intestinal Rehabilitation and Transplantation Program
1825 Fourth St., Sixth Floor
San Francisco, CA 94158
Phone: (877) 762-6935

More about David Quan


UCSF, PharmD 1991


UCSF, Clinical Pharmacy 1992

Selected Research and Publications

  1. Radhakrishnan K, Chi A, Quan DJ, Roberts JP, Terrault NA. Short Course of Postoperative Hepatitis B Immunoglobulin Plus Antivirals Prevents Reinfection of Liver Transplant Recipients. Transplantation. 2017 09; 101(9):2079-2082.
  2. Burrell C, Tsourounis C, Quan D. Impact of a pharmacist-driven protocol to improve drug allergy documentation at a university hospital. Hosp Pharm. 2013 Apr; 48(4):302-7.
  3. Hickey MD, Quan DJ, Chin-Hong PV, Roberts JP. Use of rifabutin for the treatment of a latent tuberculosis infection in a patient after solid organ transplantation. Liver Transpl. 2013 Apr; 19(4):457-61.
  4. Dong K, Quan DJ. Appropriately assessing renal function for drug dosing. Nephrol Nurs J. 2010 May-Jun; 37(3):304-8.
  5. Quan DJ. Pharmacotherapy of hepatitis C virus infection: a brief review. Nephrol Nurs J. 2009 May-Jun; 36(3):333-7.
  6. Quan DJ. A brief history in nephrology pharmacotherapy. Nephrol Nurs J. 2009 Mar-Apr; 36(2):223-7.
  7. Quan DJ. Pharmacotherapy of hepatitis B infection: a brief review. Nephrol Nurs J. 2008 Sep-Oct; 35(5):507-10, 534.
  8. Quan DJ. A primer on pharmacokinetics. Nephrol Nurs J. 2008 Mar-Apr; 35(2):213-5.
  9. Niemann CU, Behrends M, Quan D, Eilers H, Gropper MA, Roberts JP, Hirose R. Recombinant factor VIIa reduces transfusion requirements in liver transplant patients with high MELD scores. Transfus Med. 2006 Apr; 16(2):93-100.
  10. Quan DJ, Peters MG. Antiviral therapy: nucleotide and nucleoside analogs. Clin Liver Dis. 2004 May; 8(2):371-85.
  11. Reinus JF, Persky S, Burkiewicz JS, Quan D, Bass NM, Davern TJ. Severe liver injury after treatment with the leukotriene receptor antagonist zafirlukast. Ann Intern Med. 2000 Dec 19; 133(12):964-8.
  12. Chang GJ, Mahanty HD, Quan D, Freise CE, Ascher NL, Roberts JP, Stock PG, Hirose R. Experience with the use of sirolimus in liver transplantation--use in patients for whom calcineurin inhibitors are contraindicated. Liver Transpl. 2000 Nov; 6(6):734-40.
  13. Hirose R, Roberts JP, Quan D, Osorio RW, Freise C, Ascher NL, Stock PG. Experience with daclizumab in liver transplantation: renal transplant dosing without calcineurin inhibitors is insufficient to prevent acute rejection in liver transplantation. Transplantation. 2000 Jan 27; 69(2):307-11.

Publications are derived from MEDLINE/PubMed and provided by UCSF Profiles, a service of the Clinical & Translational Science Institute (CTSI) at UCSF. Researchers can make corrections and additions to their publications by logging on to UCSF Profiles.

This health care professional is not a member of UCSF Medical Group. Please check with your health insurance plan regarding coverage for services.